Mylan shares fell sharply in after-hours trading Tuesday after the local generic drug giant reported lower than projected profits for the fourth quarter and surprised analysts with an even lower than expected forecast for 2019.
The company, which is run from executive offices in Cecil, said earnings for the quarter sunk to $51.2 million, or 10 cents per share, down from $244.3 million, or 46 cents, a year earlier on lower revenue.
Excluding special items, adjusted earnings fell 9 percent to $1.30 per share, missing the consensus on Wall Street of $1.36.
Revenue fell 5 percent to $3.08 billion, reflecting a 16 percent decline in sales in the company’s North America segment.
The segment was dragged down by a lengthy restructuring at the company’s flagship plant in Morgantown, W.Va., where Mylan has been working to fix manufacturing problems outlined in a November warning letter from the U.S. Food and Drug Administration involving cross-contamination of drug ingredients and other issues.
For all of 2018, Mylan posted profits of $352.5 million, or 68 cents per share, down from $696 million, or $1.30, in 2017.
Read More
Adjusted profits for 2018 were flat at $4.58 per share vs. $4.56, while revenue slipped 4 percent to $11.4 billion from $11.9 billion.
The company is forecasting adjusted earnings per share between $3.80 and $4.80 for this year — significantly lower than analysts were expecting — citing higher sales, marketing and research and development costs.
“Our business model is predicated on prioritizing long-term sustainable growth,” CEO Heather Bresch said in a statement explaining the planned increase in spending.
In August, Mylan announced its board was conducting a strategic review aimed at “unlocking the true value” of the company.
Ms. Bresch told analysts Tuesday that the review committee’s work was almost done, but she didn’t elaborate.
“My understanding is they are nearing completion of the review,” she said.
Mylan released its financial results after the close of the stock market.
Before the release, shares were down 35 cents, or 1 percent, to close Tuesday at $30.62.
Shares fell another 10 percent in after-hours trading.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.